@article{Jones_C-2020_111858,
title = {Reply to comment on “The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic”},
author = {Jones, C. and Radhakrishna, G. and Aitken, K. and Bridgewater, J. and Corrie, P. and Eatock, M. and Goody, R. and Ghaneh, P. and Good, J. and Grose, D. and Holyoake, D. and Hunt, A. and Jamieson, N. and Palmer, D. and Soonawalla, Z. and Valle, J. and Hawkins, M. and Mukherjee, S.},
month = {nov},
year = {2020},
abstract = {We read with interest Arshad et al.’s thoughts on our guidance, which was made available to and revised in response to feedback from clinicians from the outset of the COVID-19 pandemic.We note that the authors have not commented on any specific aspect of the article’s content; instead proffering their appraisal of the authors, coupled with a call for business as usual alongside an inference that amidst an unprecedented pivot in NHS care towards patients with COVID-19 at a time when up to a fifth of medical staff were off work, such guidance was redundant.The in-excess of 2200 downloads of, and over 400 visits to, the treatment protocols and webpages respectively associated with this guidance suggest such conjecture to be erroneous, but we fully dissect their multiple assumptions in turn here.},
pages = {679-680},
volume = {124},
journal = {British Journal of Cancer},
publisher = {Springer Nature},
url = {https://doi.org/10.1038/s41416-020-01133-8},
}
